Skip to content Skip to footer
Sandoz

Sandoz Introduces Tyruko (Biosimilar, Tysabri) for Multiple Sclerosis in Germany 

Shots :  Sandoz has introduced Tyruko (natalizumab), biosimilar of Tysabri for the treatment of r/r multiple sclerosis (RRMS), in Germany which will be available from Feb 1   Polpharma Biologics is responsible for the development, manufacturing and supply of Tyruko while Sandoz holds its commercialization rights in all markets as per a global commercialization agreement signed…

Read more

PharmShots Interview In Conversation with Biogen’s Vice President, Monica Mann, Where she Shares Insights on The Publication of Data from the NOVA Study to Treat Multiple Sclerosis

PharmShots Interview: In Conversation with Biogen’s Vice President, Monica Mann, Where she Shares Insights on The Publication of Data from the NOVA Study to Treat Multiple Sclerosis

Shots: Monica spoke about the data from the NOVA P-IIIb study evaluating the efficacy of its lead candidate in Multiple Sclerosis(MS) Monica also talked about the clinical trial results and formulation of the advanced product in MS The interview gives a view of Biogen’s developing molecules in the pipeline for MS Smriti: Can you share with…

Read more

PharmaShots Interview Biogen’s Monica Mann Shares Insights on the New Real-World Data on Tysabri & Vumerity for the Treatment of Multiple Sclerosis

PharmaShots Interview: Biogen’s Monica Mann Shares Insights on the New Real-World Data on Tysabri & Vumerity for the Treatment of Multiple Sclerosis

In an interview with PharmaShots, Monica Mann, Vice President, Medical Affairs for Global MS and Pipeline at Biogen shared her views on the data of Tysabri, Vumerity & highlights of new digital health research to predict multiple sclerosis disease progression Shots: Monica spoke about detailed results of the new real-world & clinical data on the long-term use of Tysabri & real-world analyses…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]